Low-molecular-weight anti-HIV-1 agents targeting HIV-1 capsid proteins

The HIV-1 capsid is a shell that encapsulates viral RNA, and forms a conical structure by assembling oligomers of capsid (CA) proteins. Since the CA proteins are highly conserved among many strains of HIV-1, the inhibition of the CA function could be an appropriate goal for suppression of HIV-1 repl...

Full description

Saved in:
Bibliographic Details
Published inRSC advances Vol. 13; no. 3; pp. 2156 - 2167
Main Authors Kobayakawa, Takuya, Yokoyama, Masaru, Tsuji, Kohei, Fujino, Masayuki, Kurakami, Masaki, Onishi, Takato, Boku, Sayaka, Ishii, Takahiro, Miura, Yutaro, Shinohara, Kouki, Kishihara, Yuki, Ohashi, Nami, Kotani, Osamu, Murakami, Tsutomu, Sato, Hironori, Tamamura, Hirokazu
Format Journal Article
LanguageEnglish
Published England Royal Society of Chemistry 06.01.2023
The Royal Society of Chemistry
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The HIV-1 capsid is a shell that encapsulates viral RNA, and forms a conical structure by assembling oligomers of capsid (CA) proteins. Since the CA proteins are highly conserved among many strains of HIV-1, the inhibition of the CA function could be an appropriate goal for suppression of HIV-1 replication, but to date, no drug targeting CA has been developed. Hydrophobic interactions between two CA molecules through Trp184 and Met185 in the protein are known to be indispensable for conformational stabilization of the CA multimer. In our previous study, a small molecule designed by in silico screening as a dipeptide mimic of Trp184 and Met185 in the interaction site was synthesized and found to have significant anti-HIV-1 activity. In the present study, molecules with different scaffolds based on a dipeptide mimic of Trp184 and Met185 have been designed and synthesized. Their significant anti-HIV activity and their advantages compared to the previous compounds were examined. The present results should be useful in the design of novel CA-targeting anti-HIV agents. Design and synthesis of MKN-3 derivatives: a new class of small molecules, MKN-3 derivatives, were developed based on in silico screening, as dipeptide mimics of Trp184 and Met185 at the hydrophobic interaction site between two capsid (CA) proteins.
AbstractList The HIV-1 capsid is a shell that encapsulates viral RNA, and forms a conical structure by assembling oligomers of capsid (CA) proteins. Since the CA proteins are highly conserved among many strains of HIV-1, the inhibition of the CA function could be an appropriate goal for suppression of HIV-1 replication, but to date, no drug targeting CA has been developed. Hydrophobic interactions between two CA molecules through Trp184 and Met185 in the protein are known to be indispensable for conformational stabilization of the CA multimer. In our previous study, a small molecule designed by screening as a dipeptide mimic of Trp184 and Met185 in the interaction site was synthesized and found to have significant anti-HIV-1 activity. In the present study, molecules with different scaffolds based on a dipeptide mimic of Trp184 and Met185 have been designed and synthesized. Their significant anti-HIV activity and their advantages compared to the previous compounds were examined. The present results should be useful in the design of novel CA-targeting anti-HIV agents.
The HIV-1 capsid is a shell that encapsulates viral RNA, and forms a conical structure by assembling oligomers of capsid (CA) proteins. Since the CA proteins are highly conserved among many strains of HIV-1, the inhibition of the CA function could be an appropriate goal for suppression of HIV-1 replication, but to date, no drug targeting CA has been developed. Hydrophobic interactions between two CA molecules through Trp184 and Met185 in the protein are known to be indispensable for conformational stabilization of the CA multimer. In our previous study, a small molecule designed by in silico screening as a dipeptide mimic of Trp184 and Met185 in the interaction site was synthesized and found to have significant anti-HIV-1 activity. In the present study, molecules with different scaffolds based on a dipeptide mimic of Trp184 and Met185 have been designed and synthesized. Their significant anti-HIV activity and their advantages compared to the previous compounds were examined. The present results should be useful in the design of novel CA-targeting anti-HIV agents.The HIV-1 capsid is a shell that encapsulates viral RNA, and forms a conical structure by assembling oligomers of capsid (CA) proteins. Since the CA proteins are highly conserved among many strains of HIV-1, the inhibition of the CA function could be an appropriate goal for suppression of HIV-1 replication, but to date, no drug targeting CA has been developed. Hydrophobic interactions between two CA molecules through Trp184 and Met185 in the protein are known to be indispensable for conformational stabilization of the CA multimer. In our previous study, a small molecule designed by in silico screening as a dipeptide mimic of Trp184 and Met185 in the interaction site was synthesized and found to have significant anti-HIV-1 activity. In the present study, molecules with different scaffolds based on a dipeptide mimic of Trp184 and Met185 have been designed and synthesized. Their significant anti-HIV activity and their advantages compared to the previous compounds were examined. The present results should be useful in the design of novel CA-targeting anti-HIV agents.
The HIV-1 capsid is a shell that encapsulates viral RNA, and forms a conical structure by assembling oligomers of capsid (CA) proteins. Since the CA proteins are highly conserved among many strains of HIV-1, the inhibition of the CA function could be an appropriate goal for suppression of HIV-1 replication, but to date, no drug targeting CA has been developed. Hydrophobic interactions between two CA molecules through Trp184 and Met185 in the protein are known to be indispensable for conformational stabilization of the CA multimer. In our previous study, a small molecule designed by in silico screening as a dipeptide mimic of Trp184 and Met185 in the interaction site was synthesized and found to have significant anti-HIV-1 activity. In the present study, molecules with different scaffolds based on a dipeptide mimic of Trp184 and Met185 have been designed and synthesized. Their significant anti-HIV activity and their advantages compared to the previous compounds were examined. The present results should be useful in the design of novel CA-targeting anti-HIV agents. Design and synthesis of MKN-3 derivatives: a new class of small molecules, MKN-3 derivatives, were developed based on in silico screening, as dipeptide mimics of Trp184 and Met185 at the hydrophobic interaction site between two capsid (CA) proteins.
The HIV-1 capsid is a shell that encapsulates viral RNA, and forms a conical structure by assembling oligomers of capsid (CA) proteins. Since the CA proteins are highly conserved among many strains of HIV-1, the inhibition of the CA function could be an appropriate goal for suppression of HIV-1 replication, but to date, no drug targeting CA has been developed. Hydrophobic interactions between two CA molecules through Trp184 and Met185 in the protein are known to be indispensable for conformational stabilization of the CA multimer. In our previous study, a small molecule designed by in silico screening as a dipeptide mimic of Trp184 and Met185 in the interaction site was synthesized and found to have significant anti-HIV-1 activity. In the present study, molecules with different scaffolds based on a dipeptide mimic of Trp184 and Met185 have been designed and synthesized. Their significant anti-HIV activity and their advantages compared to the previous compounds were examined. The present results should be useful in the design of novel CA-targeting anti-HIV agents.
The HIV-1 capsid is a shell that encapsulates viral RNA, and forms a conical structure by assembling oligomers of capsid (CA) proteins. Since the CA proteins are highly conserved among many strains of HIV-1, the inhibition of the CA function could be an appropriate goal for suppression of HIV-1 replication, but to date, no drug targeting CA has been developed. Hydrophobic interactions between two CA molecules through Trp184 and Met185 in the protein are known to be indispensable for conformational stabilization of the CA multimer. In our previous study, a small molecule designed by in silico screening as a dipeptide mimic of Trp184 and Met185 in the interaction site was synthesized and found to have significant anti-HIV-1 activity. In the present study, molecules with different scaffolds based on a dipeptide mimic of Trp184 and Met185 have been designed and synthesized. Their significant anti-HIV activity and their advantages compared to the previous compounds were examined. The present results should be useful in the design of novel CA-targeting anti-HIV agents.
Author Onishi, Takato
Kurakami, Masaki
Boku, Sayaka
Miura, Yutaro
Sato, Hironori
Tamamura, Hirokazu
Murakami, Tsutomu
Ishii, Takahiro
Kishihara, Yuki
Fujino, Masayuki
Kobayakawa, Takuya
Yokoyama, Masaru
Tsuji, Kohei
Kotani, Osamu
Shinohara, Kouki
Ohashi, Nami
AuthorAffiliation Institute of Biomaterials and Bioengineering
AIDS Research Center
Showa Pharmaceutical University
Tokyo Medical and Dental University (TMDU)
National Institute of Infectious Diseases
Pathogen Genomics Center
AuthorAffiliation_xml – sequence: 0
  name: AIDS Research Center
– sequence: 0
  name: Pathogen Genomics Center
– sequence: 0
  name: Institute of Biomaterials and Bioengineering
– sequence: 0
  name: Showa Pharmaceutical University
– sequence: 0
  name: National Institute of Infectious Diseases
– sequence: 0
  name: Tokyo Medical and Dental University (TMDU)
Author_xml – sequence: 1
  givenname: Takuya
  surname: Kobayakawa
  fullname: Kobayakawa, Takuya
– sequence: 2
  givenname: Masaru
  surname: Yokoyama
  fullname: Yokoyama, Masaru
– sequence: 3
  givenname: Kohei
  surname: Tsuji
  fullname: Tsuji, Kohei
– sequence: 4
  givenname: Masayuki
  surname: Fujino
  fullname: Fujino, Masayuki
– sequence: 5
  givenname: Masaki
  surname: Kurakami
  fullname: Kurakami, Masaki
– sequence: 6
  givenname: Takato
  surname: Onishi
  fullname: Onishi, Takato
– sequence: 7
  givenname: Sayaka
  surname: Boku
  fullname: Boku, Sayaka
– sequence: 8
  givenname: Takahiro
  surname: Ishii
  fullname: Ishii, Takahiro
– sequence: 9
  givenname: Yutaro
  surname: Miura
  fullname: Miura, Yutaro
– sequence: 10
  givenname: Kouki
  surname: Shinohara
  fullname: Shinohara, Kouki
– sequence: 11
  givenname: Yuki
  surname: Kishihara
  fullname: Kishihara, Yuki
– sequence: 12
  givenname: Nami
  surname: Ohashi
  fullname: Ohashi, Nami
– sequence: 13
  givenname: Osamu
  surname: Kotani
  fullname: Kotani, Osamu
– sequence: 14
  givenname: Tsutomu
  surname: Murakami
  fullname: Murakami, Tsutomu
– sequence: 15
  givenname: Hironori
  surname: Sato
  fullname: Sato, Hironori
– sequence: 16
  givenname: Hirokazu
  surname: Tamamura
  fullname: Tamamura, Hirokazu
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36712613$$D View this record in MEDLINE/PubMed
BookMark eNptkt9PFDEQxxuCAUReeMds4osxWeyP3f54MSEoQrzExCivzWxvbinutWfblfjfu-cBAmFeOpl-5ptvO_OSbIcYkJBDRo8ZFeb9nCegUgv1c4vscdrImlNpth_ku-Qg52s6hWwZl2yH7Aqp1pnYI2ezeFMv44BuHCDVN-j7q1JBKL4-v7isWQU9hpKrAqnH4kNfbcoOVtnPq1WKBX3Ir8iLBQwZD27PffLj7NP30_N69vXzxenJrHaNaUrNmOANtBJbJzTyztCOGwpSKseMZoisYy1HA1ox6RgsqNYGNTglTEdhIfbJh43uauyWOHeTtwSDXSW_hPTHRvD28U3wV7aPv63RolFSTgJvbwVS_DViLnbps8NhgIBxzJYrxahuDF2jb56g13FMYXreRMnWcNNQNVGvHzq6t3L3xRNAN4BLMeeEC-t8geLj2qAfLKN2PUj7kX87-TfIL1PLuyctd6rPwkcbOGV3z_3fCvEXFjilig
CitedBy_id crossref_primary_10_1248_cpb_c23_00618
crossref_primary_10_3390_genes14061194
crossref_primary_10_1016_j_drudis_2023_103581
crossref_primary_10_1186_s43094_024_00652_y
Cites_doi 10.1074/jbc.M411141200
10.1002/bip.22920
10.1016/S0140-6736(07)60597-2
10.1016/j.ejmech.2018.09.029
10.1016/j.bmcl.2015.11.103
10.1074/jbc.M110017200
10.1128/JVI.77.9.5439-5450.2003
10.1039/b306613b
10.1002/cmdc.201500590
10.1002/cmdc.201000548
10.35772/ghm.2020.01040
10.1016/j.bmc.2019.02.013
10.1128/JVI.00227-10
10.1002/cmdc.201100542
10.1021/acs.jmedchem.0c01153
10.1128/AAC.00985-13
10.1128/AAC.02574-15
10.1021/acs.jmedchem.0c00015
10.1126/science.283.5398.80
10.3389/fcimb.2022.916487
10.1099/0022-1317-75-6-1469
10.1073/pnas.82.10.3481
10.1128/AAC.01876-21
10.1084/jem.186.8.1389
10.1016/j.virusres.2006.07.001
10.1038/s41591-019-0560-x
10.1128/AAC.03909-14
10.1006/bbrc.1998.9871
10.2174/1570162X14999160224103555
10.1038/nature09640
10.1021/ja0111941
10.1021/jm060009x
10.3390/v13030479
10.1016/j.bmcl.2012.11.041
10.1038/nature12162
10.1021/cb400075f
10.1016/j.bmc.2011.12.055
10.1016/j.bmc.2020.115923
10.1016/S0022-2836(03)00289-4
10.1073/pnas.82.20.7096
10.1016/j.bmc.2007.09.010
10.1016/j.bmcl.2009.10.098
10.1371/journal.ppat.1001220
10.1016/j.bmcl.2019.01.011
10.1016/j.bmc.2020.115488
10.1016/j.ejmech.2021.113848
10.2174/1568026619666190712204603
10.1007/978-981-10-7691-6
10.1016/S0140-6736(07)60571-6
10.1002/cbic.201900187
10.1021/jm1003528
10.1007/BF00124456
10.1006/viro.1998.9398
10.1128/jvi.71.5.3474-3483.1997
10.1016/j.bmc.2010.07.050
10.1016/j.bmc.2013.05.060
10.1016/j.apsb.2018.01.012
10.1002/anie.200351024
10.1128/JVI.05006-11
10.1128/AAC.01039-21
10.1016/j.jmb.2007.07.070
10.1128/jvi.69.7.4519-4523.1995
10.3389/fmicb.2019.01227
10.1021/ci990307l
10.1039/C9RA05869A
10.1128/JVI.00845-18
10.1021/ol500210z
10.1021/ja107447w
10.1002/1521-3773(20020816)41:16<2937::AID-ANIE2937>3.0.CO;2-J
10.3390/biom11020208
10.1016/j.bmc.2015.06.020
10.1038/s41586-020-2443-1
10.1021/jacs.8b02982
10.1126/science.2992081
10.1016/j.cell.2009.04.063
10.1021/cb400495h
10.1128/jvi.62.11.3993-4002.1988
ContentType Journal Article
Copyright This journal is © The Royal Society of Chemistry.
Copyright Royal Society of Chemistry 2023
This journal is © The Royal Society of Chemistry 2023 The Royal Society of Chemistry
Copyright_xml – notice: This journal is © The Royal Society of Chemistry.
– notice: Copyright Royal Society of Chemistry 2023
– notice: This journal is © The Royal Society of Chemistry 2023 The Royal Society of Chemistry
DBID AAYXX
CITATION
NPM
7SR
8BQ
8FD
JG9
7X8
5PM
DOI 10.1039/d2ra06837k
DatabaseName CrossRef
PubMed
Engineered Materials Abstracts
METADEX
Technology Research Database
Materials Research Database
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
Materials Research Database
Engineered Materials Abstracts
Technology Research Database
METADEX
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic

CrossRef

Materials Research Database
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
EISSN 2046-2069
EndPage 2167
ExternalDocumentID PMC9834766
36712613
10_1039_D2RA06837K
d2ra06837k
Genre Journal Article
GrantInformation_xml – fundername: ;
  grantid: 20H03362; 22K08615
– fundername: ;
  grantid: 18fk0410004; JP22fk0410042; JP22ama121043
GroupedDBID -JG
0-7
0R~
53G
AAFWJ
AAHBH
AAIWI
AAJAE
AARTK
AAWGC
AAXHV
ABEMK
ABGFH
ABPDG
ABXOH
ACGFS
ADBBV
ADMRA
AEFDR
AENEX
AESAV
AFLYV
AFVBQ
AGEGJ
AGRSR
AGSTE
AHGCF
AKBGW
ALMA_UNASSIGNED_HOLDINGS
ANUXI
APEMP
ASKNT
AUDPV
BCNDV
BLAPV
BSQNT
C6K
EBS
EE0
EF-
GROUPED_DOAJ
H13
HZ~
H~N
J3I
M~E
O9-
OK1
PGMZT
R7C
R7G
RCNCU
RPM
RPMJG
RRC
RSCEA
RVUXY
SLH
SMJ
ZCN
AAYXX
ABIQK
AFPKN
CITATION
NPM
7SR
8BQ
8FD
JG9
7X8
5PM
ID FETCH-LOGICAL-c494t-11324a56e5c38e2b90b290a667c1981ee1b152e9a8716c1af0889e8ac739b0af3
ISSN 2046-2069
IngestDate Thu Aug 21 18:38:43 EDT 2025
Fri Jul 11 16:19:58 EDT 2025
Mon Jun 30 04:37:50 EDT 2025
Mon Jul 21 06:00:06 EDT 2025
Tue Jul 01 04:20:26 EDT 2025
Thu Apr 24 22:51:22 EDT 2025
Tue Dec 17 20:59:07 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
License This journal is © The Royal Society of Chemistry.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c494t-11324a56e5c38e2b90b290a667c1981ee1b152e9a8716c1af0889e8ac739b0af3
Notes Electronic supplementary information (ESI) available: Experimental procedures including characterization data of novel synthetic compounds. See DOI
https://doi.org/10.1039/d2ra06837k
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-4773-8793
0000-0003-2788-2579
0000-0001-9786-2608
OpenAccessLink http://dx.doi.org/10.1039/d2ra06837k
PMID 36712613
PQID 2765929407
PQPubID 2047525
PageCount 12
ParticipantIDs pubmed_primary_36712613
crossref_primary_10_1039_D2RA06837K
rsc_primary_d2ra06837k
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9834766
proquest_miscellaneous_2771084906
proquest_journals_2765929407
crossref_citationtrail_10_1039_D2RA06837K
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-01-06
PublicationDateYYYYMMDD 2023-01-06
PublicationDate_xml – month: 01
  year: 2023
  text: 2023-01-06
  day: 06
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Cambridge
PublicationTitle RSC advances
PublicationTitleAlternate RSC Adv
PublicationYear 2023
Publisher Royal Society of Chemistry
The Royal Society of Chemistry
Publisher_xml – name: Royal Society of Chemistry
– name: The Royal Society of Chemistry
References Kobayakawa (D2RA06837K/cit25/1) 2019; 20
Mizuguchi (D2RA06837K/cit30/1) 2015; 23
Sakyiamah (D2RA06837K/cit15/1) 2019; 27
Thenin-Houssier (D2RA06837K/cit53/1) 2016; 14
Liu (D2RA06837K/cit66/1) 2005; 280
Mitsuya (D2RA06837K/cit5/1) 1985; 82
Nomura (D2RA06837K/cit28/1) 2013; 8
Kelly (D2RA06837K/cit47/1) 2007; 373
Tanaka (D2RA06837K/cit13/1) 2010; 132
Yoshimura (D2RA06837K/cit17/1) 2010; 84
Zhang (D2RA06837K/cit62/1) 2021; 226
Ohashi (D2RA06837K/cit19/1) 2016; 11
Griesbeck (D2RA06837K/cit79/1) 2002; 124
Jiang (D2RA06837K/cit56/1) 2019; 9
Tamamura (D2RA06837K/cit3/1) 2018
Ghosh (D2RA06837K/cit6/1) 2007; 15
Murakami (D2RA06837K/cit9/1) 1997; 186
Mizuguchi (D2RA06837K/cit18/1) 2016; 26
Suzuki (D2RA06837K/cit27/1) 2010; 18
Yant (D2RA06837K/cit58/1) 2019; 25
Thenin-Houssier (D2RA06837K/cit52/1) 2016; 60
Chia (D2RA06837K/cit64/1) 2021; 65
Ganser (D2RA06837K/cit37/1) 1999; 283
Tang (D2RA06837K/cit46/1) 2003; 327
Freed (D2RA06837K/cit39/1) 1998; 251
Pornillos (D2RA06837K/cit38/1) 2011; 469
HIV Sequence Database (D2RA06837K/cit74/1)
Rankovic (D2RA06837K/cit54/1) 2018; 92
Fujii (D2RA06837K/cit11/1) 2003; 42
Kobayakawa (D2RA06837K/cit20/1) 2019; 29
Tsuji (D2RA06837K/cit32/1) 2020; 28
Mitsuya (D2RA06837K/cit1/1) 2020; 2
Yamada (D2RA06837K/cit16/1) 2010; 20
Suzuki (D2RA06837K/cit26/1) 2010; 53
Sun (D2RA06837K/cit63/1) 2020; 63
Zhao (D2RA06837K/cit72/1) 2013; 497
Luescher (D2RA06837K/cit78/1) 2014; 16
Nomura (D2RA06837K/cit24/1) 2013; 21
Ohashi (D2RA06837K/cit2/1) 2017; 41
Narumi (D2RA06837K/cit29/1) 2012; 20
Wu (D2RA06837K/cit55/1) 2018; 158
Yan (D2RA06837K/cit68/1) 2022; 12
Mervis (D2RA06837K/cit35/1) 1988; 62
Yoshinaga (D2RA06837K/cit70/1) 2015; 59
Sun (D2RA06837K/cit60/1) 2020; 63
Suzuki (D2RA06837K/cit45/1) 2002; 277
Palani (D2RA06837K/cit65/1) 2006; 49
Zentner (D2RA06837K/cit41/1) 2013; 23
Sahani (D2RA06837K/cit61/1) 2021; 13
Fredrich (D2RA06837K/cit77/1) 2018; 140
Link (D2RA06837K/cit59/1) 2020; 584
Singh (D2RA06837K/cit71/1) 2019; 10
Cannon (D2RA06837K/cit43/1) 1997; 71
Zhang (D2RA06837K/cit67/1) 2018; 8
Dicker (D2RA06837K/cit69/1) 2022; 66
Nomura (D2RA06837K/cit23/1) 2012; 7
Tamamura (D2RA06837K/cit10/1) 1998; 253
Blair (D2RA06837K/cit48/1) 2010; 6
Wildman (D2RA06837K/cit76/1) 1999; 39
Kobayakawa (D2RA06837K/cit21/1) 2021; 64
Pornillos (D2RA06837K/cit36/1) 2009; 137
Tsuji (D2RA06837K/cit33/1) 2021; 30
Goudreau (D2RA06837K/cit50/1) 2013; 8
Tamamura (D2RA06837K/cit12/1) 2003; 1
Singh (D2RA06837K/cit57/1) 2019; 10
Cahn P (D2RA06837K/cit7/1) 2007; 369
Von Schwedler (D2RA06837K/cit73/1) 2003; 77
Sarnqadharan (D2RA06837K/cit34/1) 1985; 82
Mizuguchi (D2RA06837K/cit31/1) 2017; 108
Gerber (D2RA06837K/cit82/1) 1995; 9
Grinsztejn (D2RA06837K/cit8/1) 2007; 369
Niedrig (D2RA06837K/cit42/1) 1994; 75
Lamorte (D2RA06837K/cit51/1) 2013; 57
Tanaka (D2RA06837K/cit14/1) 2011; 6
Harada (D2RA06837K/cit83/1) 1985; 229
Kortagere (D2RA06837K/cit49/1) 2012; 86
Otaka (D2RA06837K/cit22/1) 2002; 41
Maeda (D2RA06837K/cit4/1) 2019; 19
Morikawa (D2RA06837K/cit44/1) 1995; 69
Bukrinskaya (D2RA06837K/cit40/1) 2007; 124
Kobayakawa (D2RA06837K/cit75/1) 2021; 11
References_xml – issn: 2008
  publication-title: AMBER 10
  doi: Case Darden Cheatham III
– issn: 2017
  issue: 41
  publication-title: Amino Acids, Peptides and Proteins
  doi: Ohashi Tamamura
– volume-title: Triad National Security, LLC for the U.S. Department of Energy's National Nuclear Security Administration
  doi: HIV Sequence Database
– issn: 2018
  publication-title: Mid-size drugs based on peptides and peptidomimetics: A New Drug Category
  doi: Tamamura Kobayakawa Ohashi
– issn: 2019
  publication-title: Molecular Operating Environment (MOE), 2019.01
– volume: 280
  start-page: 11259
  year: 2005
  ident: D2RA06837K/cit66/1
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M411141200
– volume: 108
  start-page: e22920
  year: 2017
  ident: D2RA06837K/cit31/1
  publication-title: Peptide Science
  doi: 10.1002/bip.22920
– volume: 369
  start-page: 1261
  year: 2007
  ident: D2RA06837K/cit8/1
  publication-title: Lancet
  doi: 10.1016/S0140-6736(07)60597-2
– volume: 158
  start-page: 478
  year: 2018
  ident: D2RA06837K/cit55/1
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2018.09.029
– volume: 26
  start-page: 397
  year: 2016
  ident: D2RA06837K/cit18/1
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2015.11.103
– volume: 277
  start-page: 2437
  year: 2002
  ident: D2RA06837K/cit45/1
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M110017200
– volume: 77
  start-page: 5439
  year: 2003
  ident: D2RA06837K/cit73/1
  publication-title: J. Virol.
  doi: 10.1128/JVI.77.9.5439-5450.2003
– volume: 1
  start-page: 3663
  year: 2003
  ident: D2RA06837K/cit12/1
  publication-title: Org. Biomol. Chem.
  doi: 10.1039/b306613b
– volume: 11
  start-page: 940
  year: 2016
  ident: D2RA06837K/cit19/1
  publication-title: ChemMedChem
  doi: 10.1002/cmdc.201500590
– volume: 6
  start-page: 834
  year: 2011
  ident: D2RA06837K/cit14/1
  publication-title: ChemMedChem
  doi: 10.1002/cmdc.201000548
– volume: 2
  start-page: 53
  year: 2020
  ident: D2RA06837K/cit1/1
  publication-title: Glob. Health Med.
  doi: 10.35772/ghm.2020.01040
– volume: 27
  start-page: 1130
  year: 2019
  ident: D2RA06837K/cit15/1
  publication-title: Bioorg. Med. Chem.
  doi: 10.1016/j.bmc.2019.02.013
– volume: 84
  start-page: 7558
  year: 2010
  ident: D2RA06837K/cit17/1
  publication-title: J. Virol.
  doi: 10.1128/JVI.00227-10
– volume: 7
  start-page: 205
  year: 2012
  ident: D2RA06837K/cit23/1
  publication-title: ChemMedChem
  doi: 10.1002/cmdc.201100542
– volume: 64
  start-page: 1481
  year: 2021
  ident: D2RA06837K/cit21/1
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.0c01153
– volume: 57
  start-page: 4622
  year: 2013
  ident: D2RA06837K/cit51/1
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.00985-13
– volume: 60
  start-page: 2195
  year: 2016
  ident: D2RA06837K/cit52/1
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.02574-15
– volume: 63
  start-page: 4790
  year: 2020
  ident: D2RA06837K/cit63/1
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.0c00015
– volume: 283
  start-page: 80
  year: 1999
  ident: D2RA06837K/cit37/1
  publication-title: Science
  doi: 10.1126/science.283.5398.80
– volume: 12
  start-page: 916487
  year: 2022
  ident: D2RA06837K/cit68/1
  publication-title: Front. Cell. Infect. Microbiol.
  doi: 10.3389/fcimb.2022.916487
– volume: 75
  start-page: 1469
  year: 1994
  ident: D2RA06837K/cit42/1
  publication-title: J. Gen. Virol.
  doi: 10.1099/0022-1317-75-6-1469
– volume: 82
  start-page: 3481
  year: 1985
  ident: D2RA06837K/cit34/1
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.82.10.3481
– volume: 66
  start-page: e01876-21
  year: 2022
  ident: D2RA06837K/cit69/1
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.01876-21
– volume: 186
  start-page: 1389
  year: 1997
  ident: D2RA06837K/cit9/1
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.186.8.1389
– volume: 124
  start-page: 1
  year: 2007
  ident: D2RA06837K/cit40/1
  publication-title: Virus Res.
  doi: 10.1016/j.virusres.2006.07.001
– volume: 25
  start-page: 1377
  year: 2019
  ident: D2RA06837K/cit58/1
  publication-title: Nat. Med.
  doi: 10.1038/s41591-019-0560-x
– volume: 59
  start-page: 397
  year: 2015
  ident: D2RA06837K/cit70/1
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.03909-14
– ident: D2RA06837K/cit74/1
– volume: 253
  start-page: 877
  year: 1998
  ident: D2RA06837K/cit10/1
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1006/bbrc.1998.9871
– volume: 14
  start-page: 270
  year: 2016
  ident: D2RA06837K/cit53/1
  publication-title: Curr. HIV Res.
  doi: 10.2174/1570162X14999160224103555
– volume: 469
  start-page: 424
  year: 2011
  ident: D2RA06837K/cit38/1
  publication-title: Nature
  doi: 10.1038/nature09640
– volume: 124
  start-page: 396
  year: 2002
  ident: D2RA06837K/cit79/1
  publication-title: J. Am. Chem. Soc.
  doi: 10.1021/ja0111941
– volume: 49
  start-page: 2851
  year: 2006
  ident: D2RA06837K/cit65/1
  publication-title: J. Med. Chem.
  doi: 10.1021/jm060009x
– volume: 13
  start-page: 479
  year: 2021
  ident: D2RA06837K/cit61/1
  publication-title: Viruses
  doi: 10.3390/v13030479
– volume: 23
  start-page: 1132
  year: 2013
  ident: D2RA06837K/cit41/1
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2012.11.041
– volume: 497
  start-page: 643
  year: 2013
  ident: D2RA06837K/cit72/1
  publication-title: Nature
  doi: 10.1038/nature12162
– volume: 8
  start-page: 1074
  year: 2013
  ident: D2RA06837K/cit50/1
  publication-title: ACS Chem. Biol.
  doi: 10.1021/cb400075f
– volume: 20
  start-page: 1468
  year: 2012
  ident: D2RA06837K/cit29/1
  publication-title: Bioorg. Med. Chem.
  doi: 10.1016/j.bmc.2011.12.055
– volume: 30
  start-page: 115923
  year: 2021
  ident: D2RA06837K/cit33/1
  publication-title: Bioorg. Med. Chem.
  doi: 10.1016/j.bmc.2020.115923
– volume: 327
  start-page: 1013
  year: 2003
  ident: D2RA06837K/cit46/1
  publication-title: J. Mol. Biol.
  doi: 10.1016/S0022-2836(03)00289-4
– volume: 82
  start-page: 7096
  year: 1985
  ident: D2RA06837K/cit5/1
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.82.20.7096
– volume: 15
  start-page: 7576
  year: 2007
  ident: D2RA06837K/cit6/1
  publication-title: Bioorg. Med. Chem.
  doi: 10.1016/j.bmc.2007.09.010
– volume: 20
  start-page: 354
  year: 2010
  ident: D2RA06837K/cit16/1
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2009.10.098
– volume: 6
  start-page: e1001220
  year: 2010
  ident: D2RA06837K/cit48/1
  publication-title: PLoS Pathog.
  doi: 10.1371/journal.ppat.1001220
– volume: 29
  start-page: 719
  year: 2019
  ident: D2RA06837K/cit20/1
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2019.01.011
– volume: 28
  start-page: 115488
  year: 2020
  ident: D2RA06837K/cit32/1
  publication-title: Bioorg. Med. Chem.
  doi: 10.1016/j.bmc.2020.115488
– volume: 226
  start-page: 113848
  year: 2021
  ident: D2RA06837K/cit62/1
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2021.113848
– volume: 19
  start-page: 1621
  year: 2019
  ident: D2RA06837K/cit4/1
  publication-title: Curr. Top. Med. Chem.
  doi: 10.2174/1568026619666190712204603
– volume-title: Mid-size drugs based on peptides and peptidomimetics: A New Drug Category
  year: 2018
  ident: D2RA06837K/cit3/1
  doi: 10.1007/978-981-10-7691-6
– volume: 41
  volume-title: Amino Acids, Peptides and Proteins
  year: 2017
  ident: D2RA06837K/cit2/1
– volume: 369
  start-page: 1235
  year: 2007
  ident: D2RA06837K/cit7/1
  publication-title: Lancet
  doi: 10.1016/S0140-6736(07)60571-6
– volume: 20
  start-page: 2101
  year: 2019
  ident: D2RA06837K/cit25/1
  publication-title: ChemBioChem
  doi: 10.1002/cbic.201900187
– volume: 53
  start-page: 5356
  year: 2010
  ident: D2RA06837K/cit26/1
  publication-title: J. Med. Chem.
  doi: 10.1021/jm1003528
– volume: 9
  start-page: 251
  year: 1995
  ident: D2RA06837K/cit82/1
  publication-title: J. Comput.-Aided Mol. Des.
  doi: 10.1007/BF00124456
– volume: 251
  start-page: 1
  year: 1998
  ident: D2RA06837K/cit39/1
  publication-title: Virology
  doi: 10.1006/viro.1998.9398
– volume: 71
  start-page: 3474
  year: 1997
  ident: D2RA06837K/cit43/1
  publication-title: J. Virol.
  doi: 10.1128/jvi.71.5.3474-3483.1997
– volume: 18
  start-page: 6771
  year: 2010
  ident: D2RA06837K/cit27/1
  publication-title: Bioorg. Med. Chem.
  doi: 10.1016/j.bmc.2010.07.050
– volume: 21
  start-page: 4452
  year: 2013
  ident: D2RA06837K/cit24/1
  publication-title: Bioorg. Med. Chem.
  doi: 10.1016/j.bmc.2013.05.060
– volume: 8
  start-page: 131
  year: 2018
  ident: D2RA06837K/cit67/1
  publication-title: Acta Pharm. Sin. B
  doi: 10.1016/j.apsb.2018.01.012
– volume: 42
  start-page: 3251
  year: 2003
  ident: D2RA06837K/cit11/1
  publication-title: Angew. Chem., Int. Ed.
  doi: 10.1002/anie.200351024
– volume: 86
  start-page: 8472
  year: 2012
  ident: D2RA06837K/cit49/1
  publication-title: J. Virol.
  doi: 10.1128/JVI.05006-11
– volume: 65
  start-page: e0103921
  year: 2021
  ident: D2RA06837K/cit64/1
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.01039-21
– volume: 373
  start-page: 355
  year: 2007
  ident: D2RA06837K/cit47/1
  publication-title: J. Mol. Biol.
  doi: 10.1016/j.jmb.2007.07.070
– volume: 63
  start-page: 4790
  year: 2020
  ident: D2RA06837K/cit60/1
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.0c00015
– volume: 69
  start-page: 4519
  year: 1995
  ident: D2RA06837K/cit44/1
  publication-title: J. Virol.
  doi: 10.1128/jvi.69.7.4519-4523.1995
– volume: 10
  start-page: 1227
  year: 2019
  ident: D2RA06837K/cit71/1
  publication-title: Front. Microbiol.
  doi: 10.3389/fmicb.2019.01227
– volume: 39
  start-page: 868
  year: 1999
  ident: D2RA06837K/cit76/1
  publication-title: J. Chem. Inf. Comput. Sci.
  doi: 10.1021/ci990307l
– volume: 9
  start-page: 28961
  year: 2019
  ident: D2RA06837K/cit56/1
  publication-title: RSC Adv.
  doi: 10.1039/C9RA05869A
– volume: 92
  start-page: e00845-18
  year: 2018
  ident: D2RA06837K/cit54/1
  publication-title: J. Virol.
  doi: 10.1128/JVI.00845-18
– volume: 16
  start-page: 1236
  year: 2014
  ident: D2RA06837K/cit78/1
  publication-title: Org. Lett.
  doi: 10.1021/ol500210z
– volume: 132
  start-page: 15899
  year: 2010
  ident: D2RA06837K/cit13/1
  publication-title: J. Am. Chem. Soc.
  doi: 10.1021/ja107447w
– volume: 41
  start-page: 2937
  year: 2002
  ident: D2RA06837K/cit22/1
  publication-title: Angew. Chem., Int. Ed.
  doi: 10.1002/1521-3773(20020816)41:16<2937::AID-ANIE2937>3.0.CO;2-J
– volume: 11
  start-page: 208
  year: 2021
  ident: D2RA06837K/cit75/1
  publication-title: Biomolecules
  doi: 10.3390/biom11020208
– volume: 23
  start-page: 4423
  year: 2015
  ident: D2RA06837K/cit30/1
  publication-title: Bioorg. Med. Chem.
  doi: 10.1016/j.bmc.2015.06.020
– volume: 584
  start-page: 614
  year: 2020
  ident: D2RA06837K/cit59/1
  publication-title: Nature
  doi: 10.1038/s41586-020-2443-1
– volume: 140
  start-page: 6432
  year: 2018
  ident: D2RA06837K/cit77/1
  publication-title: J. Am. Chem. Soc.
  doi: 10.1021/jacs.8b02982
– volume: 229
  start-page: 563
  year: 1985
  ident: D2RA06837K/cit83/1
  publication-title: Science
  doi: 10.1126/science.2992081
– volume: 137
  start-page: 1282
  year: 2009
  ident: D2RA06837K/cit36/1
  publication-title: Cell
  doi: 10.1016/j.cell.2009.04.063
– volume: 8
  start-page: 2235
  year: 2013
  ident: D2RA06837K/cit28/1
  publication-title: ACS Chem. Biol.
  doi: 10.1021/cb400495h
– volume: 62
  start-page: 3993
  year: 1988
  ident: D2RA06837K/cit35/1
  publication-title: J. Virol.
  doi: 10.1128/jvi.62.11.3993-4002.1988
– volume: 10
  start-page: 1227
  year: 2019
  ident: D2RA06837K/cit57/1
  publication-title: Front. Microbiol.
  doi: 10.3389/fmicb.2019.01227
SSID ssj0000651261
Score 2.383672
Snippet The HIV-1 capsid is a shell that encapsulates viral RNA, and forms a conical structure by assembling oligomers of capsid (CA) proteins. Since the CA proteins...
SourceID pubmedcentral
proquest
pubmed
crossref
rsc
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2156
SubjectTerms Chemistry
Conical bodies
Hydrophobicity
Proteins
Synthesis
Title Low-molecular-weight anti-HIV-1 agents targeting HIV-1 capsid proteins
URI https://www.ncbi.nlm.nih.gov/pubmed/36712613
https://www.proquest.com/docview/2765929407
https://www.proquest.com/docview/2771084906
https://pubmed.ncbi.nlm.nih.gov/PMC9834766
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1db9Mw0GLbA7wgvgaFMQXBC6oyEjt14sepMJUP8TDaaTxVZ9dlpayd2kZV-fWc7dhpaR8GL1F1uTqJ73xfPt8R8gaV5FAPAWKUAxBnA8pjGCQmy0JIVI-AVoTN8v3KO73s02Xrsg5l29MlC3mifu88V_I_VEUY0tWckv0HyoZBEYC_kb54RQrj9VY0_jJdxte-v228tFHOJk7VKO58vIjTJvyw59dctreJCTiwght816Yt0TCqonW-Rve3tk8LqHd5cMmvYAxLa2d2YVyuoBYW4-kKrsEd-5nDrAyhgHn502UKTK_0KLAJAm2zb4u9Ksej9bADZTbswGvpRNGxRmK4PisnegfMi1e2xkZsQ1a2-Jrepanry7El0xNmSqK-p-enCUd3-nOtufxu_V8KLaQZ2g12Jvr1f_fIAUV_AgXiwflF7_J7CMehJZZSW103fIQvZsvEu3qATfNlyyfZTq3dm_lOMtZi6T4g9ytXIzp1fPOQ3NGTR-Ru23f4e0zOdvFPVPNP5PgnCvwTObDjn8jzzxPSO_vQbXfiqq9GrDKRLeI0RSsaWly3FCs0lSKRVCTAea5SUaRapxKtOi3AONMqhaFJhdMFqJwJmcCQHZL9yXSin5Eo0YqhCiikLHQGKZVqkA0lY1RoxjNVNMhbP119VRWdN71PfvW3adMgrwPujSu1shPryM96v1qK8z7NTXaAyJK8QV6F2zibZvcLJnpaGhw0potMJLxBnjoihccwnhvqswbJN8gXEEwR9s07k9GVLcYuCpblHMc8REIH_AGdgX3f8fNbfdULcq9eZEdkfzEr9Uu0dhfy2EaJjit-_QPpiqi3
linkProvider Royal Society of Chemistry
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Low-molecular-weight+anti-HIV-1+agents+targeting+HIV-1+capsid+proteins&rft.jtitle=RSC+advances&rft.au=Kobayakawa%2C+Takuya&rft.au=Yokoyama%2C+Masaru&rft.au=Tsuji%2C+Kohei&rft.au=Fujino%2C+Masayuki&rft.date=2023-01-06&rft.issn=2046-2069&rft.eissn=2046-2069&rft.volume=13&rft.issue=3&rft.spage=2156&rft.epage=2167&rft_id=info:doi/10.1039%2FD2RA06837K&rft.externalDBID=n%2Fa&rft.externalDocID=10_1039_D2RA06837K
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2046-2069&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2046-2069&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2046-2069&client=summon